Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Dendermonde – page 115

2 119 clinical trials in Dendermonde, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dendermonde at a glance
2 119
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 119 trials in Dendermonde

Open in trial search

Malignant melanoma

Not recruiting

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Long-term Safety Study of Onasemnogene Abeparvovec for Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Onasemnogene Abeparvovec
  • Sponsor:Novartis Pharma AG

Uveal melanoma

Not recruiting

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Ideaya Biosciences Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

HIV infection

Not recruiting

Study of IMC-M113V for Patients with Chronic HIV Infection Who Are Virologically Suppressed

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IMC-M113V
  • Sponsor:Immunocore Limited

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Anaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neoplasm+2

Not recruiting

Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Enliven Therapeutics Inc.

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Dendermonde

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluating new therapeutic approaches for reducing cardiovascular risks.

  • Atherosclerotic cardiovascular disease prevention
  • Lipid management therapies
  • Cardiovascular risk reduction

Cutting-edge trials examining novel compounds for improving cardiovascular outcomes.

02 Cardiac Rhythm Disorders

Studies investigating treatments for atrial fibrillation and stroke prevention. Research comparing new anticoagulation therapies with established treatments for preventing systemic embolism.

  • Stroke prevention in AF
  • Novel anticoagulants
  • Cardioembolic event prevention

Advanced clinical research focusing on improving outcomes in cardiac rhythm management.

03 Specialized Cardiac Conditions

Research targeting rare cardiac conditions including transthyretin amyloidosis with cardiomyopathy. Evaluation of innovative treatments for specific cardiac pathologies.

  • Cardiomyopathy management
  • Rare cardiac diseases
  • Targeted therapeutic approaches

Focused studies on improving survival rates and quality of life in specialized cardiac conditions.

04 Stroke Management

Clinical trials examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Studies evaluating new therapeutic options for stroke prevention and management.

  • Post-stroke care
  • TIA management
  • Stroke prevention strategies

Development of advanced treatments for better stroke outcomes.

05 Oncology Research

Studies investigating the role of acetylsalicylic acid in improving survival rates for colon cancer patients. Research focused on preventing cancer recurrence after surgical intervention.

  • Colon cancer treatment
  • Post-surgical care
  • Cancer recurrence prevention

Innovative approaches in cancer survival improvement strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.